uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Clinical Neurophysiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
2015 (English)In: Journal of the Neurological Sciences, ISSN 0022-510X, E-ISSN 1878-5883, Vol. 356, no 1-2, 90-96 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: Reliable biological markers for patients with the autoimmune neuromuscular disorder myasthenia gravis (MG) are lacking. We determined whether levels of the circulating immuno-microRNAs miR-150-5p and miR-21-5p were elevated in sera from clinically heterogeneous MG patients, with and without immunosuppression, as compared to healthy controls and patients with other autoimmune disorders. Methods: Sera from 71 MG patients and 55 healthy controls (HC) were analyzed for the expression levels of miR-150-5p and miR-21-5p with qRT-PCR. Sera were also assayed from 23 patients with other autoimmune disorders (AID; psoriasis, Addison's and Crohn's diseases). Results: 34 MG patients had no immunosuppressive drug treatment (MG-0) and 37 patients were under stable immunosuppressive drug treatment since a 6 months (MG + IMM). Serum levels of miR-150-5p and miR-21-5p were higher in the MG-0 patients compared to HC (p < 0.0001). Further, miR-150-5p levels were 41% lower and miR-21-5p levels were 25% lower in the MG + IMM compared to MG-0 (p = 0.0051 and 0.0419). In the AID patients, mean miR-150-5p and miR-21-5p were comparable with healthy controls (p = 0.66). Conclusions: The immuno-microRNAs miR-150-5p and miR-21-5p show a disease specific signature, which suggests these microRNAs as possible biological autoimmune markers of MG. (C) 2015 The Authors. Published by Elsevier B.V.

Place, publisher, year, edition, pages
2015. Vol. 356, no 1-2, 90-96 p.
Keyword [en]
Myasthenia gravis, MG, MicroRNA, miR150-5p, miR21-5p, Autoimmune disorders
National Category
Neurosciences Neurology
URN: urn:nbn:se:uu:diva-264040DOI: 10.1016/j.jns.2015.06.019ISI: 000360950800016PubMedID: 26095457OAI: oai:DiVA.org:uu-264040DiVA: diva2:859274
EU, FP7, Seventh Framework Programme, 242210 'FIGHT-MG'Swedish Research Council, VR-523-2014-2048Swedish Cancer Society, 12 0504 13 0410
Available from: 2015-10-06 Created: 2015-10-05 Last updated: 2015-10-06Bibliographically approved

Open Access in DiVA

fulltext(521 kB)89 downloads
File information
File name FULLTEXT01.pdfFile size 521 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Punga, Anna RostedtAlimohammadi, MohammadPunga, Tanel
By organisation
Clinical NeurophysiologyDermatology and VenereologyDepartment of Medical Biochemistry and Microbiology
In the same journal
Journal of the Neurological Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 89 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 382 hits
ReferencesLink to record
Permanent link

Direct link